Abstract
In a patient with acute myeloid leukaemia, treated with several courses of chemotherapy including a fludarabine-containing regimen, severe symptoms due to Epstein-Barr virus reactivation occurred but could be successfully treated with the monoclonal anti-CD20 antibody rituximab. Depletion of viral host cells may be effective in treatment of symptoms due to Epstein-Barr virus reactivation.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20 / immunology
-
Antineoplastic Agents / therapeutic use*
-
Herpesvirus 4, Human / isolation & purification*
-
Herpesvirus 4, Human / physiology
-
Humans
-
Leukemia, Myeloid / drug therapy*
-
Leukemia, Myeloid / immunology
-
Leukemia, Myeloid / virology*
-
Lymphocyte Depletion
-
Male
-
Rituximab
-
Virus Activation*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Antineoplastic Agents
-
Rituximab